You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dipeptidyl-Peptidase IV Inhibitors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA

Not yet recruiting
  • Cerebral Infarction
  • +2 more
  • Dipeptidyl peptidase-4 inhibitor
  • (no location specified)
Apr 5, 2023

PreDiabetes, Type 2 Diabetes Trial in Johor Bahru (Dipeptidyl-Peptidase IV Inhibitors)

Completed
  • PreDiabetes
  • Type 2 Diabetes
  • Dipeptidyl-Peptidase IV Inhibitors
  • Johor Bahru, Johor, Malaysia
    Hospital Sultan Ismail
Mar 13, 2022

COVID 19, Coronavirus, Diabetes, Type 2 Trial in Be'er Ya'aqov, Petah tikva (Linagliptin 5 MG)

Terminated
  • COVID 19
  • +14 more
  • Linagliptin 5 MG
  • Be'er Ya'aqov, Israel
  • +2 more
May 28, 2021

Time in Range Trial in Cairo (Dipeptidyl peptidase-4 inhibitors)

Completed
  • Time in Range
  • Dipeptidyl peptidase-4 inhibitors
  • Cairo, Egypt
    Nancy Elbarbary
Aug 26, 2023

Metformin and DPP4 Inhibitors on Cognition and Cardiovascular

Recruiting
  • Type 2 Diabetes Mellitus
  • Cairo, Al Kasr Al Aini, Egypt
    National Institute of diabetes and endocrinology
Jun 19, 2022

Type 2 Diabetes, Hypertension Trial in Nashville (Placebo, Sitagliptin, Aprepitant)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Hypertension
  • Placebo
  • +3 more
  • Nashville, Tennessee
    Vanderbilt University
Feb 8, 2022

Diabetes, Type 2, Severe Insulin Deficient Diabetes Trial in Beijing (Glimepiride, Sitagliptin)

Recruiting
  • Diabetes Mellitus, Type 2
  • Severe Insulin Deficient Diabetes
  • Beijing, Please Select, China
    Peking University People's Hospital
May 18, 2022

Type 2 Diabetic Saudi Arabia Treated With Empagliflozin to

Completed
Has Results
  • Diabetes Mellitus, Type 2
  • Abha, Saudi Arabia
  • +20 more
Feb 9, 2022

Glucose Metabolism Disorders, Diabetes, Type 2, Hypoglycemic Agents Trial in Karachi (Empagliflozin 10 MG,

Recruiting
  • Glucose Metabolism Disorders
  • +3 more
  • Empagliflozin 10 MG
  • Insulin+Metformin+DPP4 inhibitor (DPP4I)
  • Karachi, Pakistan
    SINA Shireen Jinnah colony
Nov 28, 2023

Empa PASS on Urinary Tract Malignancies

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Helsinki, Finland
  • +2 more
Aug 8, 2022

Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in

Completed
  • Diabetes Mellitus, Type 2
  • Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
  • Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Gentofte, Denmark
  • +12 more
Jan 18, 2022

Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular Trial in León (Dapagliflozin 10mg Tab, Statins (Cardiovascular

Recruiting
  • Stroke, Ischemic
  • +3 more
  • Dapagliflozin 10mg Tab
  • +3 more
  • León, Guanajuato, Mexico
    Hospital General de Zona IMSS 21
Oct 3, 2022

Type 2 Diabetes to Assess Risk of Liver Injury, Kidney Injury,

Completed
  • Diabetes Mellitus, Type 2
  • One Or Multiple Sites, United Kingdom
    RTI health solutions
Aug 2, 2022

Therapeutic Drug Use for CKD Patients

Active, not recruiting
  • Chronic Kidney Disease
  • angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
  • Jinan, Shandong, China
    Xiao Li，MD
Apr 18, 2023

Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors

Active, not recruiting
  • Bullous Pemphigoid
    • Athens, Attiki, Greece
      "Attikon" University General Hospital
    Sep 21, 2020

    ive Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

    Active, not recruiting
    • Diabetes
    • Boston, Massachusetts
      Brigham and Women's Hospital
    Mar 3, 2023

    Short Bowel Syndrome Trial in Skawina (Dipeptidyl peptidase-4 inhibitor)

    Terminated
    • Short Bowel Syndrome
    • Dipeptidyl peptidase-4 inhibitor
    • Skawina, Poland
      Stanley Dudrick's Memorial Hospital
    Apr 13, 2020

    Comparative Effectiveness of Empagliflozin in the US

    Active, not recruiting
    • Diabetes Mellitus, Type 2
    • Boston, Massachusetts
      Bringham Women Hospital
    Jan 9, 2023

    Four Second Line Pharmacological Strategies in Type 2 Diabetes

    Active, not recruiting
    • Cardiovascular Events
    • +2 more
    • SGLT2 inhibitor
    • +3 more
    • Boston, Massachusetts
      Brigham and Women's Hospital
    Feb 17, 2022

    Second-line Therapies for Type 2 Diabetes and Moderate

    Enrolling by invitation
    • Type 2 Diabetes
    • Cardiac Disease
    • Glucagon like peptide 1 receptor agonist
    • +3 more
    • Rochester, Minnesota
      Mayo Clinic Rochester
    Jan 26, 2022

    Sodium-glucose Cotransporter 2 Inhibitors Among Type 2 Diabetes

    Completed
    • Diabetes Mellitus, Type 2
    • +3 more
    • Sodium-glucose cotransporter 2 (SGLT2) inhibitors
    • +2 more
    • Montreal, Quebec, Canada
      Lady Davis Institute for Medical Research, Jewish General Hospit
    Aug 17, 2020

    Sodium-glucose Cotransporter 2 Inhibitors and Risk of

    Completed
    • Type2 Diabetes
    • +5 more
    • Sodium-glucose cotransporter 2 (SGLT2) inhibitors
    • Dipeptidyl peptidase-4 (DPP-4) inhibitors
    • Montreal, Quebec, Canada
      Lady Davis Institute for Medical Research, Jewish General Hospit
    Oct 1, 2020

    Harmonizing RCT-Duplicate Emulations In A Real World Replication

    Completed
    • Type 2 Diabetes Mellitus
    • Gothenburg, Sweden
      Research Site
    Oct 23, 2023

    Liver Cancer Trial in Chang chun (FAPI PET)

    Recruiting
    • Liver Cancer
    • FAPI PET
    • Chang chun, Jilin, China
      China-Japan Union Hospital
    Mar 28, 2023

    Bradykinin-degradating Enzymes Activities in

    Recruiting
    • Angio-Oedema Caused by Angiotensin-Converting-Enzyme Inhibitor
    • Assay of Bradykinin-degradating enzymes.
    • Grenoble, France
      Chu Grenoble Alpes
    Jan 14, 2022